North America Ophthalmology Drugs and Devices Market 2019-2027: Drug Approvals Delay and Number of Drugs in the Pipeline Restraining Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “North America Ophthalmology Drugs and Devices Market 2019-2027” report has been added to ResearchAndMarkets.com’s offering.

North American ophthalmology drugs and devices market is estimated to flourish with a CAGR of 6.10% in the forecasting years 2019-2027.

The countries of the United States and Canada together form the market for ophthalmology drugs and devices in the North American region. The Canada ophthalmology drugs and devices market is primarily driven by various grants and funding to support ophthalmology research and the high prevalence of diabetes in the country.

According to the Dalhousie University (Canada), in 2016, the Department of Ophthalmology and Visual Sciences invested funds of around $4.6 million in assessing and developing new diagnostic tools and devices to allow ophthalmologists to offer the best care by detecting the disease accurately.

This funding was aimed to support various researches in ophthalmology, with a goal of inventing new & advanced drugs and devices, which is expected to boost the growth of the ophthalmology drug and devices market in Canada. Furthermore, the high prevalence of diabetes in Canada also drives the ophthalmology drugs and devices market in the country, as the disease is a leading cause of vision loss.

According to the Canadian Diabetes Association, in 2016, around 3.5 million people in the country were living with diabetes, and the number is further expected to reach around 4.9 million by 2026. Hence, the rising prevalence of diabetes positively influences the growth of the ophthalmology drugs and devices market in Canada during the forecast period.

Competitive Outlook

Few of the prime players in this market are GlaxoSmithKline, Johnson & Johnson, Inc., Novartis International AG, Pfizer, Roche Holding AG and Santen Pharmaceutical Co., Ltd.

Key Topics Covered:

1. North America Ophthalmology Drugs and Devices Market – Summary

2. Industry Outlook

2.1. Market Definition

2.2. Porter’s Five Force Analysis

2.3. Strategic Outlook

2.4. Key Insight

2.5. Value Chain Outlook

2.6. Key Buying Standards

2.7. Supply Chain Outlook

2.8. Regulatory Framework

2.9. Market Drivers

2.9.1. Increasing Ophthalmic Disorders Due to High Blood Sugar

2.9.2. Upsurge in Healthcare Spending

2.9.3. Technological Advancement

2.10. Market Restraints

2.10.1. Expirations of Brand Patents Have Affected the Pharmaceutical Industry

2.10.2. Low Cognizance Related to Ophthalmic Drugs

2.10.3. Drug Approvals Delay and Number of Drugs in the Pipeline

2.11. Market Opportunities

2.11.1. Demand for Phacoemulsification Devices and Intraocular Lenses Is Increasing

2.12. Market Challenges

2.12.1. Difficulties Associated With the Conduct of Ocular Diseases

3. Ophthalmology Drugs and Devices Market Outlook – by Drugs and Devices

3.1. Devices

3.1.1. Diagnostic & Monitoring Equipment

3.1.1.1. Optical Coherence Tomography

3.1.1.2. Ophthalmic Ultrasound Imaging Systems

3.1.1.3. Fundus Camera Market

3.1.1.4. Ophthalmoscopes

3.1.1.5. Retinoscope

3.1.1.6. Pachymeter

3.1.1.7. Wavefront Aberrometers

3.1.1.8. Perimeters/Visual Field Analyzer

3.1.1.9. Autorefractors/Phoropter

3.1.1.10. Specular Microscope

3.1.1.11. Corneal Topographers

3.1.1.12. Other Diagnostic & Monitoring Equipment Market

3.1.2. Surgery Devices

3.1.2.1. Cataract Surgery Devices

3.1.2.2. Glaucoma Surgery Devices

3.1.2.3. Refractive Surgery Devices

3.1.2.4. Vitreoretinal Surgery Devices

3.1.3. Vision Care

3.2. Drugs

3.2.1. Glaucoma Drug

3.2.2. Retinal Disorder Drug

3.2.3. Dry Eye Drug

3.2.4. Allergic Conjunctivitis, Inflammation and Conjunctivitis Drug

3.2.5. Drugs by Use of Preservation

3.2.5.1. Preserved Drugs

3.2.5.2. Preservative-Free Drugs

4. Ophthalmology Drugs and Devices Market – Regional Outlook

4.1. The United States

4.2. Canada

5. Competitive Landscape

5.1. Allergan, Inc.

5.2. Bayer

5.3. Carl Zeiss AG

5.4. Essilor International S.A.

5.5. Glaxosmithkline

5.6. Johnson & Johnson, Inc.

5.7. Novartis International AG

5.8. Pfizer

5.9. Roche Holding AG

5.10. Santen Pharmaceutical Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/a7h8os

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900